Penumbra, Inc. filings document the regulatory record for a NYSE-listed medical-device company focused on thrombectomy technologies for stroke, pulmonary embolism, venous thromboembolism, and acute limb ischemia. Form 8-K reports cover operating results, material-event disclosures, material agreements, capital-structure matters, and clinical or regulatory updates involving its thrombectomy portfolio.
Proxy materials describe shareholder voting matters, governance practices, compensation arrangements, and capital-structure proposals. The filing record also includes disclosures on risk factors, financial condition, executive appointments and compensatory arrangements, and the company's common stock registered under the symbol PEN on the New York Stock Exchange.
Penumbra Inc (PEN) President Shruthi Narayan had 1,367 shares withheld by the issuer on October 15, 2026, to satisfy tax-withholding obligations connected with vesting of restricted stock units. The transaction was a direct disposition; her reported direct holdings afterward were 31,283 shares, a portion of which is subject to vesting.
Penumbra Inc (PEN) reported that President Shruthi Narayan had 1,230 shares of common stock withheld on September 15, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units. After this tax-withholding disposition, Narayan directly holds 32,650 shares of Penumbra common stock, and a portion of these shares remains subject to vesting.
Penumbra Inc (PEN) reported that its President, as the reporting person, received a grant of 3,060 restricted stock units (RSUs) on August 17, 2026 under Penumbra’s Amended and Restated 2014 Equity Incentive Plan. The RSUs vest in four equal annual tranches beginning August 15, 2027, subject to continued service, with an alternative vesting schedule if the Closing under a January 14, 2026 merger agreement occurs. Following this award, the reporting person holds 33,880 common shares, including 65 shares acquired through Penumbra’s Employee Stock Purchase Plan.
Barclays PLC filed a Schedule 13G reporting beneficial ownership of 2,342,118 shares of PENUMBRA INC common stock, representing 5.95% of the class as of June 30, 2026. Barclays reports 2,340,999 shares with sole voting and dispositive power and 1,119 shares with shared voting and dispositive power, held through subsidiaries including Barclays Bank Ireland PLC, Barclays Bank PLC, Barclays Capital Inc, Barclays Capital Securities Ltd, and Barclays Investment Solutions Limited.
Penumbra, Inc. reported Q2 2026 revenue of $390.0 million, up 14.9% year over year, driven by thrombectomy and embolization products, particularly in the United States. Gross margin improved to 67.9%, but net income declined to $34.8 million (diluted EPS $0.88) from $45.3 million, mainly due to higher SG&A, including acquisition-related expenses, and a higher effective tax rate.
The company has entered into a definitive agreement to be acquired by Boston Scientific Corporation for $374 per share, implying an enterprise value of approximately $14.5 billion, with consideration paid about 73% in cash and 27% in Boston Scientific stock. Penumbra ended June 30, 2026 with $205.3 million in cash and equivalents, $453.5 million in marketable investments, and generated $133.1 million of operating cash flow in the first half of 2026, supporting manufacturing expansion and R&D.
Penumbra, Inc. reported revenue of $390.0 million for the second quarter ended June 30, 2026, an increase of 14.9% compared with the second quarter of 2025. Global thrombectomy revenue was $259.0 million and global embolization and access revenue was $131.1 million.
Gross profit margin was 67.9%. Total operating expenses were $223.9 million, including $25.4 million of research and development and $198.5 million of sales, general and administrative expense, with $6.9 million related to the pending acquisition by Boston Scientific Corporation. Income from operations was $41.0 million and net income was $34.8 million. Because of the pending acquisition, the company will not provide full-year 2026 financial guidance or host a conference call to discuss these results.
Revenue growth included 17.1% growth in the United States and 7.6% growth internationally. By product category, thrombectomy revenue grew 12.5% and embolization and access revenue grew 20.0% compared with the second quarter of 2025.
Penumbra, Inc. held its Annual Meeting of Stockholders on June 18, 2026.
Stockholders elected directors Arani Bose, M.D., Bridget O'Rourke, and Surbhi Sarna, who received 21,137,932 to 24,232,264 votes For. A second proposal received 29,208,244 votes For, and a third received 24,113,038 votes For.
Out of 39,331,425 shares outstanding and entitled to vote as of April 22, 2026, 29,260,683 shares were represented in person or by proxy at the meeting.
Penumbra Inc director and CEO Adam Elsesser reported a charitable stock gift by a related trust. The Siegel/Elsesser Revocable Trust transferred 77,000 shares of Penumbra common stock as a bona fide gift, identified in the footnotes as a charitable donation to a Massachusetts school. After the transaction, the trust’s indirect holdings reported for Elsesser totaled 683,042 shares of common stock. This was a non-cash transfer at a stated price of zero per share and does not represent an open-market sale.
Penumbra, Inc. held a special meeting of stockholders on May 6, 2026 to vote on three proposals, including a Merger Proposal. At the close of business on March 26, 2026, 39,324,084 shares were outstanding and 28,665,933 shares were present in person or by proxy, constituting a quorum.
Stockholders approved the Merger Proposal by majority vote; consummation remains subject to other closing conditions in the Merger Agreement, including HSR clearance and required antitrust and foreign investment approvals or waiting‑period expirations.
Penumbra, Inc. stockholders approved all three merger-related proposals at a special meeting held on May 6, 2026, satisfying the key condition that the Merger Agreement be adopted by a majority of outstanding shares.
The company had 39,324,084 shares entitled to vote as of March 26, 2026, with 28,665,933 shares represented at the meeting, forming a quorum. The proposals each received strong support, including one with 28,564,786 votes for, 85,334 against, and 15,813 abstentions. Completion of the merger still depends on remaining closing conditions, including expiration or termination of the Hart-Scott-Rodino waiting period and clearances under certain non-U.S. antitrust, competition, or foreign investment laws.